All In Biotech

Drug Trial Radar · NCT07637942

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women With HIV in the United States

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Apr 22, 2028

Study completion Apr 22, 2028

Sponsor

Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.

Conditions

  • HIV -1 Infection

Interventions

  • Every 4-week long-acting injectable cabotegravir and rilpivirineDrug

    Long-acting injectable cabotegravir and rilpivirine, initiated pre-conception. Participants will receive these drugs as prescribed outside the study by their non-study clinical care provider.

  • Every 4-week long-acting injectable cabotegravir and rilpivirineDrug

    Long-acting injectable cabotegravir and rilpivirine, initiated post-conception. Participants will receive these drugs as prescribed outside the study by their non-study clinical care provider.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Population PK: geometric mean clearance of CAB and RPV in second trimester, third trimester, and postpartum derived from a population PK modelTime frame: Measured from study entry through six weeks postpartum
  2. Geometric mean pharmacokinetic trough of CAB and RPV from every 4 week (Q4W) CAB LA and RPV LA measured every 4 weeks in plasma in second trimester, third trimester, and postpartumTime frame: Measured from study entry through six weeks postpartum

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Site 4601, University of California, UC San Diego CRS

    La Jolla, California · Not yet recruiting

  • Site 5048, University of Southern California

    Los Angeles, California · Not yet recruiting

  • Site 5052, University of Colorado

    Aurora, Colorado · Recruiting

  • Site 5030, Emory University School of Medicine

    Atlanta, Georgia · Not yet recruiting

  • Site 4001, Lurie Children's Hospital of Chicago CRS

    Chicago, Illinois · Recruiting

  • Site 5092, Johns Hopkins University

    Baltimore, Maryland · Not yet recruiting

  • Site 5013, Jacobi Medical Center Bronx

    The Bronx, New York · Not yet recruiting

  • Site 6201, University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Site 6501, St Jude Children's Research Hospital

    Memphis, Tennessee · Not yet recruiting

  • Site 5128, Baylor College of Medicine/Texas Children's Hospital

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.